Myeloproliferative neoplasms: from origins to outcomes. - Abstract - Europe PMC
GENETICS & biology OF MYELOPROLIFERATIVE NEOPLASMS - ppt video online download
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders | NEJM
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications | Leukemia
YOU DON'T KNOW JAK: A PROGRAMMED RIBOSOMAL FRAMESHIFTING DEFECT.... EHA Library. SULIMA S. Jun 24 2017; 181704
Selected JAK/STAT mutations and resulting disorders. | Download Table
JAK INHIBITORS AND JAK2 MUTATION: WHAT'S THE CONNECTION? – MPN Research Foundation
JAK2 V617F mutation negative erythrocytosis (or how to more simply perform diagnosis and treat a patient with increased hematocrit) | Multidisciplinary Respiratory Medicine | Full Text
JAK2 and MPL Mutation Screening: What Are the Indications and How to Interpret the Results - The ASCO Post
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis | NEJM
JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing | Journal of Clinical Pathology
Polycythemia Vera - Stepwards
JAK2-A Short Review – ProPath
JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms | Haematologica
Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview - ScienceDirect
Pathogenesis of myeloproliferative neoplasms - ScienceDirect
JAK2 mutation-related disease and thrombosis. | Semantic Scholar
JAK2 mutations found in the clinic. Point mutations, duplications, and... | Download Scientific Diagram
JAK2 Reflex for Polycythemia with Interpretation
References in The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis - Mayo Clinic Proceedings